Calcium pentosan polysulfate and sodium pentosan polysulfate may be used to treat intervertebral disc degeneration

Medical Hypotheses

Volumn 76, Issue 4, 2011, Pages 610-613

  Zhao, Jia Guo ^a,b   Wang, Jia ^a,b   Xin, Qi ^c   Zhang, Peng ^d   Zhang, Sheng Fei ^e   Qi, Feng ^f   Mao, Dong ^g   Zhang, Zhi Cheng ^a,b  

^a Tianjin Hospital   (China)

^b TIANJIN MEDICAL UNIVERSITY   (China)

^c Tianjin Third Central Hospital   (China)

^d THE SECOND AFFILIATED HOSPITAL OF SOOCHOW UNIVERSITY   (China)

^e NORTHERN JIANGSU PEOPLE S HOSPITAL   (China)

^f Songjiang District Center Hospital   (China)

^g Zhucheng People's Hospital   (China)

Author keywords

[No Author keywords available]

Indexed keywords

AGGRECANASE 1; AGGRECANASE 2; ANTIINFLAMMATORY AGENT; CALCIUM PENTOSAN POLYSULFATE; CHOLESTEROL; CHONDROPROTECTIVE AGENT; INTERLEUKIN 1; LIPID; MATRIX METALLOPROTEINASE; PENTOSAN POLYSULFATE; PROTEINASE; PROTEINASE INHIBITOR; PROTEOGLYCAN; TISSUE INHIBITOR OF METALLOPROTEINASE; TRIACYLGLYCEROL; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANTIINFLAMMATORY ACTIVITY; ARTICLE; ATHEROSCLEROSIS; BIOMECHANICS; CAPILLARY FLOW; CARTILAGE; CHONDROPROTECTION; CLINICAL FEATURE; COLLAGEN DEGRADATION; DRUG EFFICACY; DRUG MECHANISM; ENZYME ACTIVITY; ENZYME RELEASE; ENZYME SYNTHESIS; EXTRACELLULAR MATRIX; HEMODYNAMIC PARAMETERS; HOMEOSTASIS; HUMAN; HYPOTHESIS; INTERVERTEBRAL DISK; INTERVERTEBRAL DISK DEGENERATION; LIPID BLOOD LEVEL; LIPID METABOLISM; NONHUMAN; NUTRITION; OXYGEN TENSION; PATHOGENESIS; PH; PRESERVATION; PROTEINASE INHIBITION; PROTEOGLYCAN SYNTHESIS; THROMBOSIS; VASCULAR DISEASE; VASCULARIZATION;

EXTRACELLULAR MATRIX; HUMANS; INTERVERTEBRAL DISK DEGENERATION; PENTOSAN SULFURIC POLYESTER; PEPTIDE HYDROLASES; PROTEASE INHIBITORS;

ANIMALIA;

EID: 79952316479     PISSN: 03069877     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mehy.2011.01.016     Document Type: Article

References (52)

1. Luoma K., Riihimäki H., Luukkonen R., Raininko R., Viikari-Juntura E., Lamminen A. Low back pain in relation to lumbar disc degeneration. Spine 2000, 25(4):487-492.
2. Schwarzer A.C., Aprill C.N., Derby R., Fortin J., Kine G., Bogduk N. The prevalence and clinical features of internal disc disruption in patients with chronic low back pain. Spine 1995, 20(17):1878-1883.
3. Maniadakis N., Gray A. The economic burden of back pain in the UK. Pain 2000, 84(1):95-103.
4. Krismer M., van Tulder M. Strategies for prevention and management of musculoskeletal conditions. Low back pain (non-specific). Best Pract Res Clin Rheumatol 2007, 21(1):77-91.
5. Macfarlane G.J., Thomas E., Croft P.R., Papageorgiou A.C., Jayson M.I., Silman A.J. Predictors of early improvement in low back pain amongst consulters to general practice: the influence of pre-morbid and episode-related factors. Pain 1999, 80(1-2):113-119.
6. Nishida K., Suzuki T., Kakutani K., et al. Gene therapy approach for disc degeneration and associated spinal disorders. Eur Spine J 2008, 17(Suppl. 4):459-466.
7. Yoon S.T. Molecular therapy of the intervertebral disc. Spine J 2005, 5(Suppl. 6):280S-286S.
8. Richardson S.M., Hoyland J.A. Stem cell regeneration of degenerated intervertebral discs: current status. Curr Pain Headache Rep 2008, 12(2):83-88.
9. Kandel R., Roberts S., Urban J.P. Tissue engineering and the intervertebral disc: the challenges. Eur Spine J 2008, 17(Suppl. 4):480-491.
10. Kalson N.S., Richardson S., Hoyland J.A. Strategies for regeneration of the intervertebral disc. Regen Med 2008, 3(5):717-729.
11. Ghosh P. The pathobiology of osteoarthritis and the rationale for the use of pentosan polysulfate for its treatment. Semin Arthritis Rheum 1999, 28(4):211-267.
12. Williams S.P., Barrowcliffe T.W. The effects of post-heparin plasma lipases on anti-Xa clotting activity. Thromb Res 1985, 37(3):371-377.
13. Troeberg L., Fushimi K., Khokha R., Emonard H., Ghosh P., Nagase H. Calcium pentosan polysulfate is a multifaceted exosite inhibitor of aggrecanases. FASEB J 2008, 22(10):3515-3524.
14. Takizawa M., Yatabe T., Okada A., et al. Calcium pentosan polysulfate directly inhibits enzymatic activity of ADAMTS4 (aggrecanase-1) in osteoarthritic chondrocytes. FEBS Lett 2008, 582(19):2945-2949.
15. Smith M.M., Ghosh P., Numata Y., Bansal M.K. The effects of orally administered calcium pentosan polysulfate on inflammation and cartilage degradation produced in rabbit joints by intraarticular injection of a hyaluronate-polylysine complex. Arthritis Rheum 1994, 37(1):125-136.
16. Ghosh P., Edelman J., March L., Smith M. Effects of pentosan polysulfate in osteoarthritis of the knee: a randomized, double-blind, placebo-controlled pilot study. Curr Ther Res 2005, 66(6):552-571.
17. Edelman J., March L., Ghosh P. A double-blind placebo-controlled clinical study of a pleiotropic osteoarthritis drug (pentosan polysulphate, Cartrophen®) in 105 patients with osteoarthritis (OA) of the knee and hip joints. Osteoarthritis Cartilage 1994, 2(Suppl. 1):23.
18. Roberts S., Menage J., Duance V., Wotton S., Ayad S. 1991 Volvo Award in basic sciences. Collagen types around the cells of the intervertebral disc and cartilage end plate: an immunolocalization study. Spine 1991, 16(9):1030-1038.
19. Urban J.P., Roberts S. Degeneration of the intervertebral disc. Arthritis Res Ther 2003, 5(3):120-130.
20. Goldring M.B., Goldring S.R. Osteoarthritis. J Cell Physiol 2007, 213(3):626-634.
21. Urban J.P., Smith S., Fairbank J.C. Nutrition of the intervertebral disc. Spine 2004, 29(23):2700-2709.
22. Crock H.V., Goldwasser M., Yoshizawa H. Vascular anatomy related to the intervertebral disc. Biology of the Intervertebral Disc 1991, 109-133. CRC Press, Boca Raton. P. Ghosh (Ed.).
23. Holm S., Maroudas A., Urban J.P., Selstam G., Nachemson A. Nutrition of the intervertebral disc: solute transport and metabolism. Connect Tissue Res 1981, 8(2):101-119.
24. Urban M.R., Fairbank J.C., Etherington P.J., Loh FRCA L., Winlove C.P., Urban J.P. Electrochemical measurement of transport into scoliotic intervertebral discs in vivo using nitrous oxide as a tracer. Spine 2001, 26(8):984-990.
25. Kauppila L.I., McAlindon T., Evans S., Wilson P.W., Kiel D., Felson D.T. Disc degeneration/back pain and calcification of the abdominal aorta. A 25-year follow-up study in Framingham. Spine 1997, 22(14):1642-1647.
26. Kauppila L.I. Prevalence of stenotic changes in arteries supplying the lumbar spine. A postmortem angiographic study on 140 subjects. Ann Rheum Dis 1997, 56(10):591-595.
27. Babhulkar S. Osteonecrosis in sickle cell hemoglobinopathy. In: Urbaniak JR, Jones JPJ, editors. Osteonecrosis - etiology, diagnosis and treatment. American Orthopaedic Association; 1997. p. 131-3.
28. Olivecrona T., Bengtsson-Olivecrona G., Ostergaard P., Liu G., Chevreuil O., Hultin M. New aspects of heparin and lipoprotein metabolism. Haemostasis 1993, 23(Suppl. 1):150-160.
29. Klöcking H.P., Markwardt F. Release of plasminogen activator by pentosan polysulphate. Thromb Res 1986, 41(5):739-744.
30. Lyons G., Eisenstein S.M., Sweet M.B. Biochemical changes in intervertebral disc degeneration. Biochim Biophys Acta 1981, 673(4):443-453.
31. Adams M.A., McNally D.S., Dolan P. 'Stress' distributions inside intervertebral discs. The effects of age and degeneration. J Bone Joint Surg Br 1996, 78(6):965-972.
32. Roberts S., Caterson B., Menage J., Evans E.H., Jaffray D.C., Eisenstein S.M. Matrix metalloproteinases and aggrecanase: their role in disorders of the human intervertebral disc. Spine 2000, 25(23):3005-3013.
33. Goupille P., Jayson M.I., Valat J.P., Freemont A.J. Matrix metalloproteinases: the clue to intervertebral disc degeneration?. Spine 1998, 23(14):1612-1626.
34. Sztrolovics R., Alini M., Roughley P.J., Mort J.S. Aggrecan degradation in human intervertebral disc and articular cartilage. Biochem J 1997, 326(Pt. 1):235-241.
35. Tang B.L. ADAMTS: a novel family of extracellular matrix proteases. Int J Biochem Cell Biol 2001, 33(1):33-44.
36. Cawston T.E., Billington C. Metalloproteinases in the rheumatic diseases. J Pathol 1996, 180(2):115-117.
37. Antoniou J., Steffen T., Nelson F., et al. The human lumbar intervertebral disc: evidence for changes in the biosynthesis and denaturation of the extracellular matrix with growth, maturation, ageing, and degeneration. J Clin Invest 1996, 98(4):996-1003.
38. Goudsouzian N.M., Aebi M., Alini M. In situ hybridization of collagen types I and II RNA expression in the bovine intervertebral disc: variation with age. Trans Orthop Res Soc 1999, 24:814.
39. Pockert A.J., Richardson S.M., Le Maitre C.L., et al. Modified expression of the ADAMTS enzymes and tissue inhibitor of metalloproteinases 3 during human intervertebral disc degeneration. Arthritis Rheum 2009, 60(2):482-491.
40. Le Maitre C.L., Freemont A.J., Hoyland J.A. Localization of degradative enzymes and their inhibitors in the degenerate human intervertebral disc. J Pathol 2004, 204(1):47-54.
41. Hashimoto G., Aoki T., Nakamura H., Tanzawa K., Okada Y. Inhibition of ADAMTS4 (aggrecanase-1) by tissue inhibitors of metalloproteinases (TIMP-1,2,3 and 4). FEBS Lett 2001, 494(3):192-195.
42. Kashiwagi M., Tortorella M., Nagase H., Brew K. TIMP-3 is a potent inhibitor of aggrecanase 1 (ADAM-TS4) and aggrecanase 2 (ADAM-TS5). J Biol Chem 2001, 276(16):12501-12504.
43. Takizawa M., Ohuchi E., Yamanaka H., et al. Production of tissue inhibitor of metalloproteinases 3 is selectively enhanced by calcium pentosan polysulfate in human rheumatoid synovial fibroblasts. Arthritis Rheum 2000, 43(4):812-820.
44. Ulrich J.A., Liebenberg E.C., Thuillier D.U., Lotz J.C. ISSLS prize winner: repeated disc injury causes persistent inflammation. Spine 2007, 32(25):2812-2819.
45. Podichetty V.K. The aging spine: the role of inflammatory mediators in intervertebral disc degeneration. Cell Mol Biol 2007, 53(5):4-18.
46. Weiler C., Nerlich A.G., Bachmeier B.E., Boos N. Expression and distribution of tumor necrosis factor alpha in human lumbar intervertebral discs: a study in surgical specimen and autopsy controls. Spine 2005, 30(1):44-53.
47. Roberts S., Evans H., Menage J., et al. TNFalpha-stimulated gene product (TSG-6) and its binding protein, IalphaI, in the human intervertebral disc: new molecules for the disc. Eur Spine J 2005, 14(1):36-42.
48. Séguin C.A., Pilliar R.M., Roughley P.J., Kandel R.A. Tumor necrosis factor-alpha modulates matrix production and catabolism in nucleus pulposus tissue. Spine 2005, 30(17):1940-1948.
49. Le Maitre C.L., Freemont A.J., Hoyland J.A. The role of interleukin-1 in the pathogenesis of human intervertebral disc degeneration. Arthritis Res Ther 2005, 7(4):732-745.
50. Le Maitre C.L., Pockert A., Buttle D.J., Freemont A.J., Hoyland J.A. Matrix synthesis and degradation in human intervertebral disc degeneration. Biochem Soc Trans 2007, 35(Pt 4):652-655.
51. Kalbhen D.A. Pharmacological studies on the anti-inflammatory effect of a semi-synthetic polysaccharide (pentosan polysulfate). Pharmacology 1973, 9(2):74-79.
52. Bansal M.K., Smith M.M., Numata Y., Ghosh P. The effects of calcium pentosan polysulfate on inflammatory mediators in the rat air-pouch model of inflammation. Curr Ther Res 1993, 54(6):714-730.